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 Preterm birth, defined at birth before 37 weeks gestation, affects millions of 
newborns worldwide every year. Preterm birth is a leading cause of infant morbidity and 
mortality. One major cause of preterm birth is preterm premature rupture of membranes 
(PPROM), which can be triggered by bacterial infection and inflammation. A bacterial 
species that has been implicated in preterm birth and other obstetric complications is 
Sneathia amnii. The goals of this study were to observe cytopathogenic effects caused 
by S. amnii strain Sn35 and identify putative virulence factors causing those effects. 
Sn35 was able to adhere to, invade, and damage/kill various host cell lines. We 
	   	   	  
characterized these virulence attributes. A putative virulence determinant was identified, 
and a fragment of the protein was expressed for polyclonal antiserum production. 
Antiserum was used to characterize the expression and subcellular localization of the 
protein in Sn35. However, antiserum was unable to prevent cytopathogenic effects.  
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Introduction 
 
 
 
 
I. Bacterial Vaginosis 
 Bacterial vaginosis (BV) is the most common vaginal disorder in women of 
reproductive age. A national survey conducted from 2001-2004 estimated that BV 
affects roughly 29% of women ages 14-49 in the United States1. The development of 
BV is correlated with an imbalance of bacteria in the vagina; this imbalance is 
characterized by a decrease in healthy vaginal microorganisms and an increase in 
pathogenic microorganisms.  
 Lactobacillus species are usually the predominant bacteria found in healthy 
vaginal microflora2. As their name implies, lactobacilli are lactic acid-producing bacteria; 
lactic acid in the vagina helps to keep the pH at an acidic level. The acidity of the vagina 
is important, as it prevents many pathogenic microorganisms from colonizing and 
causing infections. Some lactobacilli can also produce hydrogen peroxide, which is toxic 
to pathogenic bacteria. The protectiveness of lactobacilli varies by species; 
Lactobacillus crispatus, for example, is known to be a protective species, due to the fact 
that most strains can produce hydrogen peroxide3. Conversely, Lactobacillus iners is 
considered a less protective species, as most strains do not produce hydrogen 
peroxide4. Reasons for the decrease in healthy vaginal bacteria have not yet been 
identified; however, studies have shown that colonization by less protective 
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Lactobacillus species are related to positive cases of BV5. There are several pathogenic 
microorganisms associated with BV, a predominant one being Gardnerella vaginalis. It 
was originally believed that G. vaginalis was the etiological cause of BV. However, not 
all women who test positive for BV are colonized with G. vaginalis6, and colonization 
with G. vaginalis does not always lead to BV. Therefore, BV is now considered a 
complex, polymicrobial disorder.  
 A multitude of risk factors for developing BV have been identified through various 
studies; these factors include but are not limited to vaginal douching7, new or multiple 
sexual partners8, the use of intrauterine contraceptive devices (IUDs)9, smoking8, and 
stressful life events10. Once developed, BV dramatically increases the risks of several 
complications, such as the susceptibility to HIV and other STIs11 and infection following 
surgical procedures, such as hysterectomies or abortions12, 13. If a pregnant woman 
develops BV, the risk of pregnancy complications, such as preterm birth and low birth 
weight, also increases14.   
 BV can present as a symptomatic or asymptomatic disorder, although roughly 
half of all BV cases are asymptomatic15. Symptoms can include abnormal vaginal 
discharge or odor, painful urination, and/or general vaginal pain. Diagnosis of BV can 
occur via two methods; the first method, the Amsel criteria, utilizes 4 different 
characteristics for a positive BV diagnosis. The first characteristic is the presence of a 
white or gray, thin, homogenous vaginal discharge. The second is the detection of clue 
cells via microscopy; clue cells are vaginal epithelial cells that have a distinct stippled 
appearance due to being covered with bacteria. The third characteristic is a vaginal fluid 
pH above 4.5, as the pH of a healthy vagina is under 4.516. The fourth and last 
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characteristic is the presence of an amine odor upon adding 10% potassium hydroxide 
solution. In order to confirm a positive BV diagnosis, 3 out of the 4 criteria mentioned 
must be present.  
 The second method for diagnosing BV, the Nugent criteria, involves using a 
Gram-stained vaginal smear to score the types and amounts of bacteria present. The 
scoring system is used to quantify the amount of long Gram-positive rods versus shorter 
Gram-negative rods and cocci. The decrease in Gram-positive rods, such as 
Lactobacillus species, is scored from 0 to 4 (with a score of 4 equaling the highest 
decrease in Gram-positive rods). The presence of small gram-variable and Gram-
negative rods, such as G. vaginalis, Prevotella species, etc., is scored from 0 to 4. The 
presence of curved Gram-negative rods, such as Mobiluncus species, is scored 0 to 217. 
Scores of 7 to 10 are consistent with cases of bacterial vaginosis.  
 For the treatment of nonpregnant woman, the CDC currently recommends an 
antibiotic regimen of 500 mg metronidazole 2x a day for a week, 0.75% metronidazole 
gel (5 g) once a day for 5 days, or 2% clindamycin cream (5 g) once a day for a week18. 
Treatment is recommended for symptomatic pregnant women, but antibiotic regimens 
are altered from those of nonpregnant women18.  
 As mentioned previously, studies have estimated that BV affects 29% of women 
in the United States1. African American women have a three-fold higher risk of bacterial 
vaginosis compared to Caucasian women (10-20% in Caucasian women, 30-50% in 
African American women); estimates can vary based upon the populations studied19, 20. 
In addition to the increased likelihood of developing BV, African American women are 
also twice as likely to experience preterm birth and have a three-fold higher risk of very 
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preterm birth21, 22. In a recent study, DNA extraction and 16S rRNA gene analysis of 
mid-vaginal isolates obtained from pregnant African American women and pregnant 
women of European ancestry revealed very significant differences in each group’s 
vaginal microbiome23. While European ancestry women are predominantly colonized 
with Lactobacillus species, the vaginal microbiomes of African American women are 
more diverse. Several bacterial taxa, such as Gardnerella, Mycoplasma, and Sneathia, 
were found more frequently in the microbiomes of African American women. These taxa 
are also associated with cases of preterm birth and microbial invasion of the amniotic 
cavity.  
 
II. Preterm Birth 
 Preterm birth, defined as birth before 37 completed weeks of pregnancy, affects 
an estimated 15 million newborns worldwide every year24. Preterm birth can be caused 
by a number of factors, including premature rupturing of the amniotic sac and release of 
amniotic fluid. While rupturing of these membranes can occur shortly before term labor 
and is termed premature rupture of membranes (PROM), rupture prior to 37 weeks 
gestation is defined as preterm PROM (PPROM). One-third of all preterm births are 
associated with PPROM25.  
 Preterm birth is a leading cause of infant morbidity and mortality worldwide26. 
Infants born prematurely may suffer from a myriad of problems, including breathing and 
feeding difficulties27, 28, hearing and vision impairments29, and developmental delays30; 
studies have also associated preterm birth with cerebral palsy31. Complications of 
preterm birth vary based on gestational age; preterm births are defined as extremely 
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preterm (<28 weeks), very preterm (28 to <32 weeks), or moderate to late preterm (32 
to <37 weeks)32, with the worst complications associated with younger gestational age. 
 Many risk factors have been correlated with experiencing preterm birth. While 
environmental factors such as stress33 and socioeconomic status34 have been 
associated with preterm labor, physical factors also play a significant role. Having 
previously experienced a premature birth35, multiple gestations (carrying twins, triplets, 
etc.)36, irregularities in reproductive organs (such as a short cervix or shortening of the 
cervix early in pregnancy)37, being underweight or overweight before pregnancy38, 39, 
and conception using in vitro fertilization (IVF)40 are physical factors that may increase 
the risk of preterm birth. As previously mentioned, race has also been correlated to 
preterm birth risk. Of the factors listed, experiencing previous preterm births is the 
greatest risk for a new preterm birth35.  
 Two additional factors have been associated with the development of PPROM. 
The first, weakening of fetal membranes, is another normal process that occurs at the 
onset of labor. However, if it occurs preterm, it can contribute to a premature delivery. 
Fetal membranes can be weakened due to collagen degradation by matrix 
metalloproteinases (MMPs). Various types of collagen are present in placental 
membranes. Studies have found that amniotic fluid isolated from cases of PPROM have 
higher levels of MMPs41, 42. The second factor, infection, has become a major target of 
interest. Bacterial infections and inflammation triggered by infections could contribute to 
weakened membranes and development of PPROM. Some bacterial factors, like 
lipopolysaccharides (LPS), have the ability to increase MMP expression43. Furthermore, 
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bacteria have been isolated from amniotic fluid obtained from PPROM44, indicating that 
the bacteria are able to ascend into and invade the amniotic cavity.  
 
III.  Microbial Invasion of the Amniotic Cavity 
 Microbial invasion of the amniotic cavity (MIAC) is defined by a culture of 
amniotic fluid (AF) that tests positive for the presence of bacteria. While less than 1% of 
AF samples isolated from women at term tested positive for bacteria, 12.8% of AF 
samples isolated from patients experiencing preterm birth with intact membranes gave 
positive results45. The same study discovered that 32.4% of AF samples obtained from 
women experiencing PPROM tested positive for bacteria. Rates may be falsely low due 
to failure to cultivate certain fastidious organisms.  
 Little is known about how bacteria gain access to the amniotic fluid; it is currently 
thought that vaginal bacteria traverse the cervical mucus plug and enter the uterine 
cavity46. This is a difficult route, as mucus plugs form specifically to act as a barrier 
between the vagina and the uterine cavity. Furthermore, the mucus plug contains a 
number of antimicrobial agents that aid in blocking bacterial infection47. After getting 
past the mucus plug, bacteria can remain in the uterine cavity, traverse into the 
placental membranes, causing chorioamnionitis, or completely pass though the 
placental membranes and access the amniotic fluid (Figure 1). Bacteria can trigger 
intraamniotic inflammation, leading to an increase in a number of factors such as IL-648, 
TNF-α49, or MMP-850. These inflammatory markers, specifically MMP-8, can degrade 
collagen present in the placental membranes, weakening them. The inflammatory  
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Figure 1. Model of microbial invasion of the amniotic cavity (MIAC). This is the 
currently accepted model for how microbes are able to access and invade the amniotic 
environment. It is thought that bacteria (shown in red) ascend through the cervical 
mucus plug and into the uterine cavity. Once in the uterus, they can invade the chorion 
layer of the placenta (indicated by the tan cells), and cause chorioamnionitis. 
Furthermore, they can travel through the fetal membranes (indicated by the gray cells) 
and access the amniotic fluid (which would be located above the gray cells). 
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Reprinted by permission from Macmillan Publishers Ltd: Nature – Laboratory 
investigations. Kim, M. J., et al., Widespread microbial invasion of the chorioamniotic 
membranes is a consequence and not a cause of intra-amniotic infection. Laboratory 
investigation; a journal of technical methods and pathology 2009, 89 (8), 924-36. 
Copyright 2009. 
http://www.nature.com/labinvest/journal/v89/n8/full/labinvest200949a.html 
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response can also trigger uterine muscle contractions. Collectively, these 
consequences can lead to PPROM and preterm birth51. 
 Several microorganisms have been associated with MIAC, PPROM, and preterm 
birth. Gardnerella vaginalis, Mycoplasma hominis, Fusobacterium species, Ureaplasma 
species, and Sneathia species have all been detected in PCR-based studies of MIAC52, 
53. Many studies utilize non-culture, DNA-based methods, as many microbial species 
have yet to be cultivated54. DNA-based methods are not able to distinguish between live 
and dead microorganisms, but can detect microorganisms that culture-based methods 
might not55.  
 
 
IV. Sneathia amnii  
 Sneathia amnii is a Gram-negative anaerobic bacterium, and is a member of the 
Fusobacteriaceae family. Formerly grouped with the genus Leptotrichia, Sneathia 
species have been isolated as part of normal reproductive microflora and in association 
with obstetric complications56, 57. Sneathia has been associated with bacterial vaginosis, 
preterm labor, and postpartum bacteremia, and has been associated with STDs. It is 
also one of the most common genera found in amniotic fluid. A novel species, Sneathia 
amnii, was isolated and characterized by the Vaginal Human Microbiome Project at 
Virginia Commonwealth University. The specific strain was isolated from a mid-vaginal 
sample obtained from an African American woman experiencing symptoms of preterm 
labor at 26 weeks gestation; this type strain was designated Sn3558.  
 Sn35 possesses a genome that is 1.34 Mbp in size; to date, this is the smallest 
genome in the Fusobacteriaceae family. The GC content of the genome is roughly 28%, 
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and an estimated 1,282 putative protein-encoding genes exist within the genome58. 
Analysis of the genome identified genes for glucose, maltose, glycogen, and 
glucosamine metabolism; however, Sn35 is unable to ferment mucin, starch, fructose, 
galactose, mannose, or sucrose. While Sn35 does not encode enzymes to synthesize 
the majority of amino acids, it appears to thrive via utilization of host factors58.  
 Antibiotic resistance of this strain was also studied. As is true for most Gram-
negative organisms, Sn35 is highly resistant to nafcillin. However, Sn35 tests sensitive 
to vancomycin, which is contrary to most Gram-negative organisms. Sn35 is also 
sensitive to metronidazole, which is commonly used to treat bacterial vaginosis58. 
 Several genes of interest were identified during analysis of the Sn35 genome. A 
putative DNA restriction-modification system was discovered; this system was predicted 
to be acting as a Type II system (Figure 2). Additionally, several genes were predicted 
to encode proteins present in Type II protein secretion systems. A large protein with 
homology to hemagglutinin domains and hemolysins was identified, yet 
hemagglutination of human red blood cells was not detected58. Sn35 exhibits weak 
hemolytic activity, but requires the presence of human blood to grow on agar plates. 
Human serum is required for growth in liquid culture. Attempts to use Brucella sheep’s 
blood agar or fetal bovine serum for Sn35 growth were unsuccessful58; these results 
demonstrate the specificity of Sn35 for its human host. This could be due to human-
specific growth factors present in blood and serum. 
 Although very little is known about this organism, due to its implications in both 
bacterial vaginosis and preterm birth, S. amnii strain Sn35 appears to be a great focus 
for further research in the context of reproductive and neonatal health. Furthermore, its  
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Figure 2. Putative Type II restriction-modification system expressed by S. amnii 
strain Sn35. A) Orange represents the restriction enzyme, while green represents both 
the methyltransferase (MT) and the methylation (M) present on DNA. B) The 
methyltransferase will methylate genomic DNA, while the restriction enzyme can 
recognize foreign DNA and attack unmethylated sites. Figure adapted from Ishikawa et 
al., 201059.  
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specificity for human blood products strongly implies its exclusive niche in humans. Its 
contributions to MIAC, PPROM, and preterm birth, as well as vaginal health as a whole, 
need to be further elucidated. 
 
V.       Research Objectives 
 As previously mentioned, Sneathia is one of the most common bacterial genera 
found in amniotic fluid; in addition, Sneathia has been implicated in a number of 
obstetric complications. Furthermore, previous work has demonstrated that S. amnii 
strain Sn35 is both cytotoxic and adherent to Me-180 human cervical cells58. These 
results suggest both the production of virulence factors by S. amnii and a possible 
mechanism of pathogenicity. Therefore, the goal of this study is to further characterize 
the pathogenicity of Sn35 in preterm birth. Three objectives were established for this 
study: 
 
 1. Determine pathogenic effects that Sn35 has on a variety of immortalized and 
primary cell lines. It was hypothesized that in order to invade the amniotic cavity and 
exist in amniotic fluid, bacteria must be able to damage and/or traverse one or more 
host cell barriers present during pregnancy. This was addressed by performing various 
host cell assays in the presence of Sn35 to determine pathogenic effects. 
 2. Identify the putative virulence factor responsible for the observed pathogenic 
effects. It was hypothesized that in order to exert a pathogenic effect on host cells, Sn35 
must be producing a virulence factor. This was addressed by performing bioinformatic 
analyses to determine whether Sn35 encoded genes with similarity to known virulence 
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factors.  
 3. Characterize the function of the putative virulence factor. It was hypothesized 
that the virulence factor could be acting as a cytotoxin or adhesin, allowing for either 
adherence/invasion of host cells or cell damage/death. This was addressed by 
attempting to clone and express the putative virulence factor in E. coli; later, polyclonal 
antiserum was used to better characterize the protein.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	   	  15	  
 
 
 
 
 
Materials and Methods 
 
 
 
 
Bacterial Strains and Culture Conditions 
 The bacterial strains and plasmids used in this study are listed in Table 1. 
Sneathia amnii strain Sn35 was grown and maintained anaerobically on supplemented 
brain heart infusion (sBHI) plates containing 1.5% (w/v) BactoAgar (BD, Franklin Lakes, 
NJ), 3.7% (w/v) BHI (Thermo Scientific, Waltham, MA), 1% (w/v) gelatin, 1% (w/v) yeast 
extract, 0.1% (w/v) starch, 0.1% (w/v) dextrose, and 10% whole human blood 
(BioChemed Services, Winchester, VA). 
 Participants were recruited from outpatient clinics at the Virginia Commonwealth 
University Medical Center from 2009-2013 as part of the Human Vaginal Microbiome 
project. The Institutional Review Boards for Human Subjects Research at VCU (Panel 
B) and the Virginia Department of Health reviewed and approved this study. Strain Sn35 
was obtained through this study. Liquid cultures of Sn35 were grown anaerobically in 
sBHI broth containing 10% pooled human serum (HS) (MP Biomedicals, Santa Ana, 
CA). All cultures were grown under anaerobic conditions in a BacBasic anaerobic 
incubator (ShelLab, Cornelius, OR) containing a gas mix of 5.0% carbon dioxide, 5.0% 
hydrogen, and nitrogen as the balance gas.  
  sBHI + chocolate agar plates were used for recovery of bacteria during 
adherence and gentamicin protection assays. Whole human blood was added to   
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Table 1. Plasmids and bacterial strains 
 
 
 
Plasmids Description Source 
pCR4-TOPO-AS01 pCR4-TOPO vector with 
TvbA fragment AS01 
cloned in 
This study 
pET32xT – AS01 pET32xT vector with TvbA 
fragment AS01 cloned in 
This study 
 
 
S. amnii Strains Description Source 
Sn35 Mid-vaginal isolate 
obtained from patient 
experiencing preterm birth 
at 26 weeks gestation 
Harwich et al. (2012) 
 
 
E. coli Strains Description Source 
CH3 Blue Chemically competent cells 
derived from E. coli K12, 
cloning strain 
Bioline (Tauton, MA) 
BL21-
CodonPlus(DE3)-RIL 
Electrocompetent cells 
derived from E. coli BL21, 
recombinant protein 
expression strain (CmR) 
Stratagene (La Jolla, CA) 
BL21 + pET32xT + 
AS01 
BL21-CodonPlus(DE3)-RIL 
cells containing TvbA 
peptide fragment (AS01) 
cloned into pET32xT 
(AmpR, CmR) 
This study 
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autoclaved sBHI agar to achieve a final concentration of 10%. The mixture was placed 
at 80°C for 30 minutes prior to pouring in order to achieve whole blood lysis. sBHI + 
chocolate agar plates were made with a concentration of 1% (w/v) BactoAgar.  
 E. coli strains were grown aerobically in LB at 37°C and 200 rpm. Appropriate 
antibiotics were added at the following concentrations: 100 µg/mL ampicillin (Amp) for 
E. coli, and 35 µg/mL chloramphenicol (Cm) for E. coli. 
 
Agarose Gels 
 1% agarose gels were prepared by dissolving agarose in 1X tris-acetate-EDTA 
(TAE) buffer. Ethidium bromide was added to the gel at a final concentration of 1 µg/mL 
before pouring. 5X DNA loading buffer blue (Bioline, Taunton, MA) was added to the 
DNA samples to achieve a 1X final concentration. Gels were run at 124 volts and 
visualized under ultraviolet (UV) light. DNA size was determined by comparison against 
the Hyperladder series of molecular weight marker (Bioline, Taunton, MA).  
 
Cell Lines 
 JEG-3 human chorionic trophoblasts (ATCC, Manassas, VA) were cultured at 
37°C in 5% CO2 in minimum essential media (EMEM) (Quality Biological, Gaithersburg, 
MD) supplemented with 10% fetal bovine serum and 1 IU mL-1 penicillin/streptomycin 
(Life Technologies, Carlsbad, CA). VK2/E6E7 human vaginal keratinocytes (ATCC, 
Manassas, VA) were cultured at 37°C in 5% CO2 in keratinocyte-SFM (Life 
Technologies, Carlsbad, CA) supplemented with human recombinant Epidermal Growth 
Factor 1-53, Bovine Pituitary Extract, and 1 IU mL-1 penicillin/streptomycin (Life 
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Technologies, Carlsbad, CA). Primary human amniotic epithelial cells (HAECs) were 
isolated from healthy, full-term placentas obtained via C-section (MCV, Richmond, VA). 
Cells were cultured at 37°C in 5% CO2 in DMEM/F12 (1:1) (Life Technologies, 
Carlsbad, CA) supplemented with 10% fetal bovine serum and 1 IU mL-1 
penicillin/streptomycin (Life Technologies, Carlsbad, CA). 
 
Trypan Blue Cytotoxicity Assay 
 Twenty-four-well polystyrene plates (CellTreat, Shirley, MA) were seeded with 
respective cell lines. Once a monolayer of cells had formed, growth medium was 
removed, the host cell monolayer was washed twice with sterile 1X PBS, and fresh 
growth medium was added. Bacterial cultures were grown overnight in 2 to 3 mL of 
SBHI/HS, and diluted to an OD600nm of 0.1. Bacterial cultures were grown overnight in 2 
to 3 mL of SBHI/HS, and diluted to an OD600nm of 0.1. Bacterial cells were resuspended 
in cell growth medium, and 100 µL of the suspension was added to each well. After a 4 
hour incubation with bacteria, host cell wells were washed 3 to 4 times with sterile 1X 
PBS. A 1:1 ratio solution of trypan blue (Thermo Scientific, Waltham, MA): sterile 1X 
PBS was added to the cell wells for 4 minutes. The trypan blue solution was removed, 
and images of each well were taken with an EVOS AMEX-100 microscope (Life 
Technologies, Carlsbad, CA). 
 
MTT Cytotoxicity Assay 
 Twenty-four-well polystyrene plates (CellTreat, Shirley, MA) were seeded and 
incubated as previously described. Growth medium was removed, the host cell 
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monolayer was washed twice with sterile 1X PBS, and fresh growth medium was 
added. Bacterial cultures were grown overnight in 2 to 3 mL of SBHI/HS, and diluted to 
an OD600nm of 0.1. Bacterial cells were resuspended in cell growth medium, and 100 µL 
of the suspension was added to each well. The plates were centrifuged at 500 rpm for 1 
minute to maximize contact between the bacteria and the host cells. After a 4 hour 
incubation with bacteria, host cell wells were washed 3 to 4 times with sterile 1X PBS 
and fresh growth medium was added. MTT (EMD Millipore, Billerica, MA) was added to 
each well, and the plates were centrifuged using the settings previously mentioned to 
maximize contact between the MTT reagent and the cells. The plates were incubated 
for 2 hours at 37°C in 5% CO2. After incubation, MTT stop solution was added 
according to the manufacturer’s instructions. Cells were transferred to a 96-well plate 
(CellTreat, Shirley, MA) for A570 and A630 readings using a plate reader (BioTek, 
Winooski, VT). Absorbance values were detected with a 1:1 mix of MTT reagent and 
stop solution alone; therefore, these values were subtracted from the experimental 
values obtained. Untreated (control) cell viability was normalized to 100% for each MTT 
assay. 
  
Bacterial Adherence Assay 
 Twenty-four-well polystyrene plates (CellTreat, Shirley, MA) were seeded and 
incubated as previously described. Growth medium was removed, the host cell 
monolayer was washed twice with sterile 1X PBS, and fresh growth medium was 
added. Bacterial cultures were grown overnight in 2 to 3 mL of SBHI/HS, and diluted to 
an OD600nm of 0.1. Bacterial cells were resuspended in cell growth medium, and 100 µL 
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of the suspension was added to each well. After a 1 hour incubation with bacteria, host 
cell wells were washed 3 to 4 times with sterile 1X PBS. Water was added to each well 
in order to lyse the host cells. The bottoms of the wells were scraped vigorously with a 
pipet tip, and all contents were collected and placed in a 1.5 mL microcentrifuge tube. 
The contents were serially diluted and plated onto sBHI + chocolate agar plates. 
Alternatively, after washing 3 to 4 times with sterile 1X PBS, DNA from each well was 
extracted using a PowerSoil DNA isolation kit (MO BIO Laboratories, Carlsbad, CA).  
 
Gentamicin Protection Assay 
 Twenty-four-well plates (CellTreat, Shirley, MA) were seeded and incubated as 
previously described. Assays were performed as described previously for bacterial 
adherence assays, except bacterial cultures were diluted to an OD600nm of 0.001. After a 
1 hour incubation with bacteria, host cell wells were washed 3 to 4 times with sterile 1X 
PBS and antibiotic-free cell media was added. Gentamicin was added to each well at a 
final concentration of 100 µg/mL. Cells were incubated at 37°C in 5% CO2 for 1 hour, 
then washed 2 to 3 times with sterile 1X PBS. Water was added to each well in order to 
lyse the host cells. The bottoms of the wells were scraped vigorously with a pipet tip, 
and all contents were collected and placed in a 1.5 mL microcentrifuge tube. The 
contents were serially diluted and plated onto sBHI + chocolate agar plates. 
 
Adherence/Invasion Assay Utilizing Confocal Microscopy 
 Confocal assays were performed as previously described60 with slight 
modifications. Individual glass bottom plates (MatTek, Ashland, MA) were seeded with 
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respective cell lines. Once a monolayer of cells had formed, growth medium was 
removed, the cell monolayer was washed twice with sterile 1X PBS, and stained with 
2.5 µL/mL per plate of Vybrant DiI (Invitrogen, Grand Island, NY) membrane stain 
(Invitrogen, Grand Island, NY) for 15 minutes at 37°C in 5% CO2. After incubation, cells 
were washed twice with sterile 1X PBS to remove excess stain. 
 Bacterial cultures were grown overnight in 2 to 3 mL of SBHI/HS, and diluted to 
an OD600nm of 0.150. 1.4 mL of the culture was centrifuged to collect the cells. Bacterial 
cells were washed twice with sterile 1X PBS and stained with 5 µL of BacLight green 
bacterial stain (Invitrogen, Grand Island, NY) in 1 mL 1X PBS. Bacterial cells were 
incubated with the stain for 15 minutes at 37°C in 5% CO2, then washed twice with 1X 
PBS to remove excess stain. 100 µL of bacteria in 1 mL 1X PBS were added per 
individual plate of host cells. Plates were incubated for 15 minutes at 37°C in 5% CO2. 
Cell monolayers were washed twice with sterile 1X PBS to remove nonadherent 
bacteria. Plates were analyzed by confocal microscopy using a Zeiss LSM 710 Confocal 
Microscope. Microscopy was performed at the VCU – Dept. of Anatomy and 
Neurobiology Microscopy Facility, supported, in part, by funding from NIH-NINDS 
Center Core Grant 5 P30 NS047463 and, in part, by funding from NIH-NCI Cancer 
Center Support Grant P30 CA016059. 
 
Quantitative Polymerase Chain Reaction (qPCR)  
 DNA isolated from adherence/invasion assays was used to determine the relative 
amount of adhesive/invasive bacteria using 16S primers. The reaction mix was 
composed of 5 µL of undiluted DNA, 10 pmol of both the forward and reverse primers,  
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Table 2. Primer List 
 
 
 
Primer Name Sequence 
AgSn35Fwd 5’ ATGATGGGATCCGCAGAAAATATTTCAAAAAC 3’  
AgSn35Rev 5’ ATGATGCTCGAGTTGACCAGAGTTAGCTTCTACTTTAC 3’ 
SnRTFwd 
(for qPCR) 
5’ TGATCCAGCAATTCTGTGTG 3’ 
SnRTRev (for 
qPCR) 
5’ TAGGCAAGCCTATGGTTGAG 3’ 
 
  
	   	   	  23	  
5.5 µL sterile water, and 12.5 µL iTaq Universal SYBR Green Supermix (Bioline, 
Tauton, MA). qPCR was performed in an iQ5 Multicolor Realtime PCR Detection 
system (BioRad, Hercules, CA) following the programmed steps: 1 cycle at 94°C for 2 
minutes, 45 cycles of 94°C for 15 seconds, 52°C for 15 seconds, 71°C for 15 seconds  
while collecting real time-PCR readings, and 31 cycles of 65°C for 10 seconds while 
collecting melting curve recordings. Data was recorded in cycle threshold (Ct) for each 
sample in technical triplicate, averaged, and normalized by calculating 2(-Ct). Ratios were 
determined between input control values and experimental values to determine 
differences in amount of bacteria. 
  
In silico Prediction of Antigenic Regions 
 The amino acid sequence of TvbA was submitted to an antigenic peptide 
predictor, which predicted the segments within the protein sequence likely to be 
antigenic using the methods of Kolaskar and Tongaonkar61. 
 
Polymerase chain reaction (PCR) and Product Purification 
 Reaction mixtures were generally 50 µL total volume composed of 10 µL 5X 
Phire buffer (Thermo Scientific, Waltham, MA), 1 µL 10 mM dNTPs (2.5 mM of each), 
10 pmol of both the forward and reverse primers, DNA template, and 1 µL Phire II 
polymerase in sterile water. For reactions using gDNA as template, the template was 
diluted 1:10 and 1 µL was used as template. Reaction conditions were programmed into 
a thermal cycler machine as: hot start at 105°C, initial denaturation at 98°C for 1 minute, 
followed by 35 cycles of 98°C for 30 seconds, 54°C for 30 seconds, 72°C for 45 
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seconds, and a round of final extension at 72°C for 5 minutes. Resulting PCR products 
were purified after agarose gel electrophoresis using the QIAquick Gel Extraction kit 
(Qiagen, Valencia, CA), following the manufacturer’s instructions. 
 
Plasmid DNA Purification and Manipulation 
 Plasmid purifications were performed using the QIAprep Spin Miniprep kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions, using overnight 
cultures of E. coli single colony transformants in 3 mL LB containing the appropriate 
antibiotic. All restriction enzymes, specific buffers, and BSA used for restriction digests 
of plasmid DNA or PCR products were purchased from New England Biolabs (Ipswich, 
MA) and used according to the respective manufacturer’s recommendations. After 
restriction digest, the 5’ phosphoryl groups were removed using Antarctic Phosphatase 
and supplied buffer (New England Biolabs, Ipswich, MA) according to manufacturer’s 
instructions. Ligation of DNA fragment inserts into digested plasmids was accomplished 
using Ready-To-Go T4 DNA Ligase (Amersham Biosciences, Piscataway, NJ).  
 
Transformation of Chemically Competent E. coli 
 One vial of CH3-Blue chemically competent E. coli cells (Bioline, Taunton, MA) 
was thawed on ice; 3 µL of the plasmid ligation reaction were added and incubated on 
ice for 20 minutes. The tube was transferred to a 42°C waterbath for 30 seconds; 250 
µL of SOC media (2% Bacto tryptone, 0.5% Bacto yeast extract, 10mM NaCl, 2.5mM 
KCl, 10mM MgSO4, 10mM MgCl2, 20mM glucose) was immediately added to the tube 
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after removal from the waterbath. The cells recovered at 37°C for 1 hour, and were then 
plated on LB plates with the appropriate antibiotic selection. 
Transformation of Electrocompetent E. coli 
 One vial of electrocompetent E. coli was thawed on ice; 4 µL of the plasmid 
ligation reaction were added and incubated on ice for 10 minutes. The mixture was 
transferred to a chilled electroporation cuvette with a gap length of 0.1 cm and pulsed 
once using the Micropulser machine (BioRad, Hercules CA) preset E. coli setting 1. 
Immediately following electroporation, 250 µL of SOC media was added and the entire 
mixture was transferred to a 1.5 mL microcentrifuge tube. The cells recovered at 37°C 
for 1 hour, then plated on LB plates containing the appropriate antibiotic; plates were 
incubated overnight at 37°C. 
 
Construction of Expression Plasmid 
 The primer set AgSn35Fwd (BamHI site) and AgSn35Rev (XhoI site) were used 
to PCR amplify the TvbA peptide AS01 from Sn35 gDNA with directional restriction sites 
on either end of the PCR product. After gel electrophoresis and purification by gel 
extraction, the PCR product was “A-tailed” by incubation with Taq DNA polymerase, 
which adds an adenine to the 3’ end of DNA fragments. The 15 µL reaction was 
composed of 10 µL PCR product, 1 µL 10 mM dNTPs, 2 µL sterile water, 1.5 µL Taq 
buffer, and 0.5 µL Taq; this reaction was incubated at 72°C for 15 minutes. The A-tailed 
PCR product was ligated into the pCR4-TOPO vector (Life Technologies, Carlsbad, 
CA), which is a linear vector containing single, overhanging, 3’ deoxythymidine 
residues. The 3 µL ligation reaction was composed of 2 µL of the previously A-tailed 
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PCR product, 0.5 µL salt solution provided with the vector, and 0.5 µL of the pCR4-
TOPO vector. This reaction was incubated at room temperature for 20 minutes. All 3 µL 
of the ligation reaction was used for transformation of CH3-Blue chemically competent 
E. coli cells, as described previously. Transformants were selected for on LB agar 
plates containing ampicillin. The plasmid construct was isolated and purified using the 
previously mentioned plasmid miniprep kit, and sequence fidelity of the gene insert was 
confirmed by nucleotide sequencing. 
 The pCR4-TOPO-AS01 plasmid construct was digested with BamHI and XhoI 
(New England Biolabs, Ipswich, MA) according to the manufacturer’s instructions. The 
isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible plasmid pET32xT (generously 
supplied by Dr. David Williams, VCU, Richmond, VA) was also digested with BamHI 
and XhoI. The digested PCR product was ligated into the digested plasmid using DNA 
ligase, as described previously. The plasmid construct was used for transformation of 
CH3-Blue chemically competent E. coli cells, as described previously. Transformants 
were selected for on LB agar plates containing ampicillin. The plasmid construct was 
isolated and purified using the previously mentioned plasmid miniprep kit. The 
pET32xT-AS01 plasmid construct was used to transform electrocompetent E. coli BL21-
CodonPlus (DE3)-RIL cells (Stratagene, La Jolla, CA), as described previously. 
Transformants were selected for on LB agar plates containing ampicillin and 
chloramphenicol. 
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Polyacrylamide Gel Electrophoresis 
 Gels were run using the NuPAGE SDS-PAGE system (Life Technologies, 
Carlsbad, CA). Manufacturer’s instructions were followed with slight modifications. 
Sample mixes consisted of 30 µL sample, 10 µL 4X Novex NuPAGE LDS Sample 
Buffer (Life Technologies, Carlsbad, CA), and 4 µL 10X NuPAGE Sample Reducing 
Buffer (Invitrogen, Grand Island, NY). Samples were placed in boiling water for 10 
minutes, lightly sonicated, and loaded into the wells of a NuPage 4-12% Bis-Tris 1.5 
mm gel (Invitrogen, Grand Island, NY). The gel was electrophoresed in 1X NuPAGE 
Running Buffer for 35 minutes at 200 V. Protein size was determined by comparison 
against the Precision Plus Protein Kaleidoscope standard (BioRad, Hercules, CA). 
Lanes were visualized by staining the gel with Imperial Protein Stain (Thermo Scientific, 
Waltham, MA) overnight, and destaining with water until bands were visible. 
 
Recombinant Peptide Expression  
 To induce the expression of recombinant AS01, a streak of BL21+pET32xT-
AS01 colonies was used to inoculate 270 mL of LB containing ampicillin and 
chloramphenicol. The culture was incubated with shaking overnight at 37°C. 120 mL of 
the overnight culture was transferred to 2 L of LB containing ampicillin, and individual 60 
mL aliquots of the overnight culture was transferred to 2 flasks of 1 L of LB containing 
ampicillin. The cultures were then incubated shaking at 30°C for 3 hours. A 1 mL aliquot 
of each culture was removed and saved prior to induction with 1 mM IPTG for 3 hours at 
30°C. Following protein induction, another 1 mL aliquot was removed and saved. The 
remaining culture volume was centrifuged to collect the bacterial cells. Pellets were 
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washed one time in sterile 1X PBS, and frozen at -80°C. The pre- and post-induction 
samples were run on a polyacrylamide gel, stained, and visualized in order to confirm 
proper protein expression.  
   
Recombinant Peptide Purification  
 Recombinant protein purification was conducted under denaturing conditions 
following the Probond Purification System (Life Technologies, Carlsbad, CA) with 
modifications. Each induced BL21+pET32xT-AS01 pellet was resuspended in 40 mL of 
prewarmed guanidinium lysis buffer containing one dissolved EDTA-free protease 
inhibitor tablet (Roche Diagnostics, Indianapolis, IN). Resuspended bacterial cells were 
rocked at room temperature for 10 minutes, and then sonicated 6 times for 30 seconds 
each. Cell debris was removed by centrifugation, and the supernatant was filter 
sterilized using a syringe capped with a pre-filer and a 0.45 µm pore filter. 10 mL of 
HisPur Cobalt Resin (Thermo Scientific, Waltham, MA) was washed once with sterile 
water and once with denaturing binding buffer. The filtered protein supernatant was 
applied to the beads in a 50 mL conical tube, and the tube was rocked at room 
temperature for 20 minutes. A purification column was then prepared with the protein 
supernatant + bead mixture. The column was washed once with denaturing binding 
buffer, four times with denaturing wash buffer, and one time with denaturing elution 
buffer containing no imidazole. Recombinant AS01 was eluted from the column with 5 
mL denaturing elution buffer + 500 mM imidazole; 1 mL was added and collected at a 
time. All fractions were pooled, concentrated, and loaded into a 3.5K MWCO Slide-A-
Lyzer Dialysis Cassette (Thermo Scientific, Waltham, MA) to be dialyzed overnight in 3L 
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of 10 mM Tris, pH 8.0 and 0.1% Triton X-100 stirring at 4°C. The dialyzed peptide was 
removed from the dialysis cassette and total peptide concentration was determined 
using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA). In order 
to determine the location of recombinant AS01 throughout the purification process, 
fractions of all washes and elutions were run on a polyacrylamide gel, stained, and 
visualized. 
 
Western Analysis  
 A 0.45 µm PVDF transfer membrane (Thermo Scientific, Waltham, MA) was 
soaked in an 80% methanol/20% ethanol solution, then dipped in 1X NuPage transfer 
buffer (Invitrogen, Grand Island, NY) containing 10% methanol. Transfer paper and 
sponges were also soaked in transfer buffer. After gel electrophoresis, the gel was 
prepared for electrophoretic transfer by rinsing in deionized water and then placing 
against the PVDF membrane. Transfer papers and sponges were used to maintain tight 
contact between the gel and membrane. Transfers were run in 1X NuPage transfer 
buffer at 45V for 90 minutes at room temperature. Membranes were blocked overnight 
at 4°C in 5% skim milk diluted in 1X PBS, then probed with appropriate concentrations 
of respective primary antibodies in 1X PBS + 1-1.5% blocking solution + 0.05% Tween-
20 (Fisher Scientific, Pittsburg, PA) for 1 hour at room temperature, while rocking. 
Membranes were washed three times for 10 minutes with 1X PBST (PBS + 0.05% 
Tween-20), then probed with 1:50,000-diluted goat anti-rabbit immunoglobulin-
horseradish peroxidase conjugate (Invitrogen, Grand Island, NY) in 1X PBST for 45 
minutes at room temperature, while rocking. Bands were visualized with the ECL Plus 
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western blotting detection system (GE Healthcare, Buckinghamshire, UK). Blots were 
incubated in the chemiluminescence developing reagent for 30 seconds, covered in 
plastic wrap, exposed to X-ray film, and developed in an X-O-Mat.  
 
Rabbit Polyclonal Antiserum Production 
 Recombinant AS01 was expressed and purified using methods previously 
described, and sent to New England Peptides. Prior to immunization with recombinant 
AS01, 5 mL of pre-immunized serum was collected from the rabbit (New Zealand White 
– SPF). The rabbit was immunized with recombinant AS01 3 separate times. Boosts 
were administered on days 14 and 28, while bleeds were collected on days 35 and 40. 
Upon receipt of post-immunized serum, serum was aliquoted into cryovials and stored 
at -80°C.  
 
Determining Location of TvbA Expression  
 A 5 mL overnight culture of Sn35 grown in SBHI+HS under anaerobic conditions 
was centrifuged to obtain a cell pellet; the supernatant was concentrated, and the cell 
pellet was resuspended and lysed in lysis buffer. Samples were subjected to SDS-
PAGE and Western analysis as described previously; the primary antiserum dilution 
used in this experiment was 1:2500.  
 
Temporal Protein Expression Assay 
 An overnight culture of Sn35 grown under anaerobic conditions in SBHI+HS was 
subcultured at a 1:50 dilution into fresh SBHI+HS and grown at 37°C under anaerobic 
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conditions. 1 mL samples were collected at 4, 6, 8, 12, 16, 24, and 48 hours. Cell pellets 
were obtained by centrifugation at 16,000 rpm for 5 minutes at room temperature; after 
storage at -80°C, pellets were resuspended in varying amounts of lysis buffer using 
pellet size as a rough estimation of equal protein amounts. Samples were subjected to 
SDS-PAGE and Western analysis as described previously; the primary antiserum 
dilution used in this assay was 1:500.  
 
Utilizing Antiserum in Inhibition Studies 
 Inhibition assays were performed as previously described, with modifications. 
Bacteria were incubated with varying concentrations of pre-immunized serum or post-
immunized serum for 30 minutes at 37°C in 5% CO2. Treated bacteria were then added 
to cell monolayers and changes in cytopathogenicity were observed as previously 
described.  
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Results 
 
 
 
 
I. Sn35 is Cytopathogenic to Host Cells 
 
 As previously discussed, it has been shown that Sn35 exerts cytotoxic effects on 
Me-180 human cervical carcinoma cells, as observed by cell rounding and loss of 
adherence58. Therefore, the first focus of this study was to identify additional 
cytopathogenic effects caused by Sn35; for this focus, a variety of immortalized cell 
lines were used. Immortalized cell lines were chosen due to their isolation from the 
female reproductive system and their relevance to the study. Primary human amniotic 
epithelial cells (HAECs) were also isolated and used in the study. 
 
A. Cytotoxicity to HAECs 
 Sn35 was tested for its ability to induce loss of cell integrity (measured via a 
trypan blue assay). 1.2 x 107 bacteria were added to a confluent monolayer of HAECs. 
Following a 4 hour incubation, the monolayer was washed and incubated with trypan 
blue for 4 minutes. The stain was removed and microscopic images were recorded. As 
shown in Figure 3, epithelial cells treated with Sn35 are stained blue, indicating cell 
damage and/or death due to incubation with Sn35. The trypan blue assay was repeated 
using a 3 hour incubation time with similar results. 
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Figure 3. Loss of cell integrity of HAECs due to incubation with Sn35. Bacteria 
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an 
OD600nm = 0.1, and added to HAECs for 4 hours. Cells were washed after incubation, 
and trypan blue was added for 4 minutes to determine reduction in cell integrity. Light 
microscopy images were taken after the trypan blue incubation. Experiments were also 
repeated using a 3 hour bacteria-host cell incubation.  
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B. Cytotoxicity to JEG-3 cells 
 In addition to primary cells, we analyzed the ability of Sn35 to induce loss of cell 
integrity and viability (measured via qualitative trypan blue assays and quantitative MTT 
assays) in immortalized cell lines. 1.2 x 107 bacteria were added to a confluent 
monolayer of JEG-3 human chorionic trophoblasts. Trypan blue and MTT assays were 
performed as described previously. Figure 4 shows trypan blue cell integrity results for 
JEG-3 cells. Treatment with Sn35 for 4 hours appears to inflict cell damage and/or 
death, and allows for the trypan blue stain to traverse cell membranes. The trypan blue 
assay was repeated using a 3 hour incubation time with similar results. 
 Figure 5 shows results representative of 2 biologic replicates of the MTT viability 
assay for Sn35-induced cytotoxicity. After a 4 hour incubation of JEG-3 cells with Sn35, 
the OD570nm readings, a measure of cell viability, had decreased to 25.9% relative to the 
untreated controls. Those cells treated with 100% methanol for 4 hours had a 
decreased viability of 9.7% relative to untreated controls. The MTT assay was repeated 
with similar results. 
 
C. Cytotoxicity to VK2 cells 
 The VK2 human vaginal keratinocyte cell line was also used to study cytotoxicity; 
both trypan blue assays and MTT assays were performed as described above. 
Consistent with trypan blue results from the JEG-3 cell line, exposure to Sn35 for 4 
hours appeared to induce cell damage and/or death in the VK2 cell line (Figure 6). The 
trypan blue assay was repeated using a 3 hour incubation time with similar results. 
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Figure 4. Loss of cell integrity of JEG-3 cells due to incubation with Sn35. Bacteria 
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an 
OD600nm = 0.1, and added to JEG-3 cells for 4 hours. Cells were washed after 
incubation, and trypan blue was added for 4 minutes to determine reduction in cell 
integrity. Light microscopy images were taken after the trypan blue incubation. 
Experiments were also repeated using a 3 hour bacteria-host cell incubation.  
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Figure 5. Loss of viability of JEG-3 cells due to incubation with Sn35. Bacteria 
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an 
OD600nm = 0.1, and added to JEG-3 cells for 4 hours. Cells were washed after 
incubation, and MTT was added to each well for 2 hours. After stop solution was added, 
A570nm readings were collected via a 96-well plate reader to determine cell viability. 
Statistical comparison (using student t-test) between Sn35-treated cells and the control 
cells gave a P value of <0.05. Experiments were performed twice with similar results; 
this is a representative graph of viability.  
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Figure 6. Loss of cell integrity of VK2 cells due to incubation with Sn35. Bacteria 
were grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an 
OD600nm = 0.1, and added to VK2 cells for 4 hours. Cells were washed after incubation, 
and trypan blue was added for 4 minutes to determine reduction in cell integrity. Light 
microscopy images were taken after the trypan blue incubation. Experiments were also 
repeated using a 3 hour bacteria-host cell incubation.  
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 Figure 7 shows results representative of 2 biologic replicates of the MTT viability 
assay for Sn35-induced cytotoxicity. After a 4 hour incubation of VK2 cells with Sn35, 
the OD570nm readings had decreased to 63.5% relative to the untreated controls. Those 
cells treated with 100% methanol for 4 hours had a decreased viability of 7.3% relative 
to untreated controls. The MTT assay was repeated with similar results.	  
 
II. Adherence and Invasion of Host Cells 
 
 Previous studies have also demonstrated adherence of Sn35 to the Me-180 cell 
line58. Sn35 was therefore tested for its ability to adhere to the cell lines previously 
described. In addition, Sn35 invasion of host cells was also studied, as some bacterial 
species invade host cells after adhering to their surfaces.   
 
 A. Adherence and Invasion of HAECs 
 Confocal microscopy was used to determine if Sn35 was capable of adhering 
and/or invading HAECs. Epithelial cells were stained with VyBrant DiI membrane stain, 
while bacterial cells were stained with BacLight Green bacterial stain. Cells and bacteria 
were incubated together for 15 minutes, and then cell monolayers were washed and 
imaged with a Zeiss LSM 710 Confocal Microscope. Figure 8 indicates that Sn35 is 
able to invade HAECs, as demonstrated by the fluorescence of the bacteria within the  
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Figure 7. Loss of viability of VK2 cells due to incubation with Sn35. Bacteria were 
grown in SBHI + HS anaerobically overnight. Bacteria were standardized to an OD600nm 
= 0.1, and added to VK2 cells for 4 hours. Cells were washed after incubation, and MTT 
was added to each well for 2 hours. After stop solution was added, A570nm readings were 
collected via a 96-well plate reader to determine cell viability. Statistical comparison 
(using student t-test) between Sn35-treated cells and the control cells gave a P value of 
<0.05. Experiments were performed twice with similar results; this is a representative 
graph of viability.  
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Figure 8. Invasion of Sn35 into HAECs. Bacteria were grown in SBHI + HS 
anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, and 
added to HAECs (red) for 15 minutes. Cells were washed after bacterial incubation to 
remove any nonadherent bacteria. Adherence was observed by confocal microscopy. 
Experiments were performed twice, with similar results. 
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epithelial cell. A Z-stack was also performed to confirm the presence of Sn35 within the 
cell (Figure 9). The confocal assay was performed two times with similar results.  
 
B. Adherence and Invasion of JEG-3 cells 
 Confocal assays were performed on the JEG-3 cell line as described above. 
Figure 10 shows that Sn35 appears to some interaction with this cell line; however, the 
interaction is not as pronounced as that of Sn35 and HAECs. This assay was performed 
two times with similar results.  
 In addition to confocal assays, several other adherence and invasion assays 
were performed with the JEG-3 cell line. qPCR was used to determine the amount of 
bacteria that adhered and invaded JEG-3 cells during a 1 hour incubation. Figure 11 
demonstrates that 4.2% of Sn35 added to each well was recovered by qPCR relative to 
the amount of bacterial input. The qPCR assay was performed two times with 
inconsistent results. Plating assays were also performed to obtain adherence and 
invasion percentages. Figure 12 demonstrates that, through plating recovery 
experiments, 1.7% of bacteria were able to adhere to JEG-3 cells relative to the 
bacterial input, while 0.3% of bacteria were able to invade the JEG-3 cells. Plating 
assays were performed two times with inconsistent results. 
 
C. Adherence and Invasion of VK2 cells 
 Confocal, adherence, and invasion assays were performed on the VK2 cell line 
as described above. Figure 13 demonstrates that Sn35 is able to invade VK2 cells, as 
shown by confocal microscopy. This assay was performed twice with similar results. 
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Figure 9. Z-stack of Sn35 invasion into HAECs. Successive slices of different focal 
planes were used to confirm invasion of bacteria into the cells.  
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Figure 10. Invasion of Sn35 into JEG-3 cells. Bacteria were grown in SBHI + HS 
anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, and 
added to JEG-3 cells (red) for 15 minutes. Cells were washed after bacterial incubation 
to remove any nonadherent bacteria. Adherence was observed by confocal microscopy. 
Experiments were performed twice, with similar results. 
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Figure 11. qPCR-based recovery of Sn35 after incubation with JEG-3 cells. 
Bacteria were grown anaerobically in SBHI + HS overnight. The culture was 
standardized to OD600nm = 0.1, and incubated with JEG-3 cells for 1 hour. DNA was 
extracted and subjected to qPCR with Sn35-specific 16S primers.   
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Figure 12. Adherence and invasion of JEG-3 cells by Sn35. An overnight Sn35 
culture was standardized to OD600nm = 0.1 for adherence studies and 0.001 for 
gentamicin protection studies. Cells were incubated for an hour with bacteria; 
gentamicin assays were incubated with the antibiotic for an additional hour. Percent 
adherence and invasion were calculated from CFUs plated on SBHI + chocolate agar.   
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Figure 13. Invasion of Sn35 into VK2 cells. Bacteria were grown in SBHI + HS 
anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, and 
added to VK2 cells (red) for 15 minutes. Cells were washed after bacterial incubation to 
remove any nonadherent bacteria. Adherence was observed by confocal microscopy. 
Experiments were performed twice, with similar results. 
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Figure 14 demonstrates that 7.3% of Sn35 added to each well was recovered by qPCR 
relative to the amount of bacterial input. As with the JEG-3 cell line, the qPCR assay 
was performed two times with inconsistent results. Figure 15 demonstrates that, 
through plating recovery experiments, 1.4% of bacteria were able to adhere to VK2 cells 
relative to the bacterial input, while 0% of bacteria were able to invade the VK2 cells. 
Plating assays were performed two times with inconclusive results. 
  
 
III. Identification of Putative Virulence Gene in Sn35 
 
 Bioinformatic analysis of the Sn35 genome revealed a putative virulence gene 
with homology to a number of haemagluttinin repeats and haemagglutination activity 
domains; homology to a filamentous haemagglutinin family domain was also identified. 
One well-studied filamentous haemagglutinin, FHA, is expressed by Bordetella 
pertussis. FHA is the best-studied adhesin produced by B. pertussis, and requires a 
single specific accessory protein, FhaC, for secretion. FHA and FhaC work together as 
components of a two-partner Type Vb two-partner secretion system (Figure 16). FHA 
begins as a precursor with an N-terminal signal peptide that is recognized by the Sec 
pathway machinery. Once through this machinery, FhaC both aids in the folding of FHA 
and mediates the secretion of the mature FHA protein by forming a pore in the outer 
membrane. Because a potential virulence factor was identified, additional analyses 
were performed to find a putative transporter gene in the Sn35 genome. Upstream of 
the previously identified putative virulence gene, a gene with homology to  
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Figure 14. qPCR-based recovery of Sn35 after incubation with VK2 cells. Bacteria 
were grown anaerobically in SBHI + HS overnight. The culture was standardized to 
OD600nm = 0.1, and incubated with VK2 cells for 1 hour. DNA was extracted and 
subjected to qPCR with Sn35-specific 16S primers.   
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Figure 15. Adherence and invasion of VK2 cells by Sn35. An overnight Sn35 culture 
was standardized to OD600nm = 0.1 for adherence studies and 0.001 for gentamicin 
protection studies. Cells were incubated for an hour with bacteria; gentamicin assays 
were incubated with the antibiotic for an additional hour. Percent adherence and 
invasion were calculated from CFUs plated on SBHI + chocolate agar.   
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Figure 16. Type Vb two-partner secretion system expressed by Bordetella 
pertussis, and putatively expressed by Sn35. The secreted protein is represented in 
green, and red represents the signal peptide cleaved off of the protein after 
translocation through the Sec pathway (shown in maroon). The transporter protein is 
represented in orange, which helps to fold the protein into its functional conformation 
and aids in its secretion through the outer membrane. Figure adapted from Thanassi et 
al., 200062.  
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FhaC was identified. This was not surprising, as genes encoding Type Vb two-partner 
systems are organized into operons, where the transporter gene usually precedes the 
virulence gene63. Because many virulence factors are secreted by two-partner secretion 
systems, the putative genes in Sn35 became the targets of this study. The putative 
virulence protein was designated TvbA, for putative Type Vb protein A; the putative 
transporter protein was designated TvbB, for putative Type Vb protein B. TvbA is 
approximately 1715 amino acids and 184.55 kDa in size, and TvbB is approximately 
441 amino acids and 50.63 kDa in size.  
  
IV. Polyclonal Antiserum Production Using TvbA Peptide 
 
 In order to study the newly identified TvbA, attempts to clone and express the 
full-length, functional protein were made. However, these were unsuccessful; one 
difficulty encountered was the complexity of the putative two-partner system. If TvbA 
does utilize a two-partner secretion system, the putative transporter TvbB would be 
absolutely necessary for the proper folding and secretion of the putative virulence 
protein. Therefore, both proteins would need to be cloned and expressed together in 
order to produce functional TvbA. The two-gene operon is 6.483 kb in size. Purified 
TvbA would also be difficult to obtain; inserting a purification tag between the two 
secretory components might disturb secretion, as the N-terminus of the protein encodes 
a signal sequence prior to processing. Additionally, previous studies have demonstrated 
that virulence components of two-partner systems can contain C-terminal domains that 
are removed during translocation64. If further processing occurs at the C-terminus of 
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TvbA, a C-terminal purification tag would be cleaved off and rendered useless. For 
these reasons, an alternate tactic was developed. Upstream and downstream fragments 
of TvbA were amplified via PCR, fused to a chloramphenicol resistance cassette, and 
cloned into a suicide vector for use in generating a TvbA gene interruption via allelic 
exchange. Currently, this approach has also been unsuccessful. As previously 
discussed, a genetic system has not been established for Sn35, making modification 
difficult. Due to the inability to work with recombinant full-length TvbA or purify the 
protein, polyclonal antiserum to a fragment of TvbA was produced.  
 
A. Identification of Antigenic Epitopes within TvbA 
 In order to identify the regions of TvbA with the highest antigenic propensity, the 
amino acid sequence of the full-length protein was submitted to an online antigenic 
peptide predictor, which compares the occurrence of amino acid residues in submitted 
protein sequence to those found in experimentally determined epitopes. According to 
the prediction algorithm used, if the average antigenic propensity for the whole protein is 
above 1.0, all residues with a propensity of above 1.0 are potentially antigenic. If the 
average is below 1.0, all residues with a propensity above the average of the total 
protein are potentially antigenic61. The average antigenic propensity for TvbA is 0.9937, 
according to this algorithm. The results obtained from the predictor are shown in Figure 
17.  
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Figure 17. In silico prediction of antigenic epitopes within TvbA. Average antigenic 
propensities generated for TvbA demonstrated a number of antigenic epitopes in the 
middle of the protein. The peptide targeted for antiserum production is boxed.  
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 While epitope prediction tools are helpful, they only provide estimations.  
When choosing a peptide for antiserum production, the N- or C-terminal of the full-
length protein is typically used, as those parts of the protein are usually exposed65. 
However, as previously mentioned, using the termini of TvbA as antiserum targets 
would be risky. Therefore, the middle of TvbA was targeted for eventual polyclonal 
antiserum production. It was thought that by selecting a larger peptide, the polyclonal 
antiserum would be able to detect multiple epitopes present in TvbA. This is ideal for 
our current studies, as the conformation of functional TvbA is currently not known. The 
target peptide was 60.50 kDa in size without purification tags; the vector tags added ~20 
kDa to the final peptide size. This peptide fragment is referred to as AS01. The boxed 
area in Figure 17 indicates the targeted peptide region. 
  
B. Expression and Purification of Recombinant AS01 
 AS01 was amplified by PCR as previously described (Figure 18). AS01 was 
cloned into the pCR4-TOPO vector, digested out using restriction enzymes, and 
subsequently subcloned into digested pET32xT (Figure 19). Presence of the fragment 
was confirmed via sequencing and restriction digest (Figure 20). After transformation 
into E. coli cells and verification of transformants, recombinant AS01 was expressed 
with samples collected both pre- and post-induction. Whole cell lysates obtained pre-
induction and post-induction were subjected to SDS-PAGE and visualized as previously 
described. Expression of the TvbA fragment was confirmed by the presence of an ~80 
kDa product after induction with 1 mM IPTG (Figure 21).  Expressed recombinant AS01  
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Figure 18. PCR amplification of AS01 DNA. AS01-specific primers were used to 
amplify AS01 off of the Sn35 genome. Lane 1 contains Hyperladder 1kb, and Lane 4 
contains AS01 (1680 bp in size). PCR products were run on 1% agarose DNA gel.  
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Figure 19. Schematic representation of the pET32xT-AS01 plasmid. The AS01 
peptide is shown in green. The peptide is tagged with 2 6xHis tags: one at the 5’ end of 
the insert and one at the 3’ end.  
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Figure 20. Restriction digest confirmation of pET32xT-AS01 candidates in 
chemically competent E. coli cells. Lane 1 contains Hyperladder 1kb, Lane 2 is 
empty, and Lanes 3-11 are candidates digested with XbaI. All candidates (except the 
one in Lane 8) exhibit the expected banding pattern (6547 bp and 1005 bp). Candidate 
1 (Lane 3) was used in this study.  
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Figure 21. Confirmation of induced AS01 with 1mM IPTG at 30°C. An SDS-PAGE 
gel was Imperial-stained and used to confirm the presence of AS01 after IPTG induction 
(Lane 3, boxed band). Lane 1 contains protein ladder. Lane 2 contains a pre-induced 
culture sample.  
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was purified via column purification utilizing cobalt resin (Figure 22). After dialysis, the 
purified peptide was sent to New England Peptides for polyclonal antiserum generation.  
   
C. Characterizing the Expression of TvbA in Sn35 Using AS01 Antiserum 
 AS01 antiserum was first used to identify the localization of TvbA expression in 
Sn35. To determine whether TvbA is associated with the bacterial cell surface or 
secreted into bacterial media, an overnight culture of Sn35 was centrifuged and 
separated. Fractions of cell pellets and cell supernatants were subjected to SDS-PAGE 
and Western analysis as previously described. TvbA was detected in the cell pellet 
fraction, as depicted by Figure 23, suggesting that the protein is not secreted into 
bacterial media. According to the genome sequence of Sn35, TvbA should be 184.55 
kDa in size. However, the bands detected appear to be much bigger than that. It’s 
possible that TvbA is modified in some way; it’s also possible that the protein is 
dimerizing. 
 To further characterize the expression of TvbA in a temporal context, samples of 
an actively growing Sn35 culture were collected and subjected to SDS-PAGE and 
Western analysis. TvbA appears to be expressed throughout exponential, late 
exponential, and stationary phases (Figure 24). Again, the protein is detected at a size 
above 250 kDa. However, a smaller band that appears to sit at ~180 kDa appears over 
time. This could further support the hypothesis that TvbA is dimerizing.  
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Figure 22. Purification of recombinant AS01. Fractions obtained from cobalt resin 
column purification were run on an SDS-PAGE gel and Imperial-stained. Lane 1 
contains protein ladder. Lane 2 contains a sample of culture lysate. Lane 3 contains 
flow through after initial application of culture lysate to the resin, and Lane 4 contains a 
single wash with denaturing binding buffer. Lanes 5 and 6 contain the first and last 
washes with denaturing wash buffer. Lane 7 contains one wash with denaturing elution 
buffer containing no imidazole. Lanes 8 and 9 contain the eluted AS01 peptide with 
denaturing elution buffer and 500mM imidazole (boxed), and Lane 10 indicates cobalt 
resin remaining in the column.  
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Figure 23. Characterization of the subcellular location of TvbA in Sn35. Western 
analysis using TvbA antiserum demonstrated that TvbA is localized in the cell pellet 
(Lane 3) and outer membrane proteins (Lane 4), as indicated by the boxed bands. Lane 
2 shows concentrated supernatant; TvbA was not present in that fraction. Lane 1 
contains protein ladder.  
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Figure 24. Temporal expression of TvbA by Sn35. TvbA is expressed through 
exponential, late exponential, and stationary phase. TvbA appears to be detected above 
250 kDa, as indicated by the boxed bands. Lane 1 contains protein ladder. 
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D. Inhibiting Cytotoxicity, Adherence, and/or Invasion Using AS01 Antiserum 
 Following successful detection of TvbA using antiserum, inhibition studies of 
cytotoxicity, adherence, and invasion were performed. Trypan blue assays were 
performed on the JEG-3 cell line to determine the inhibition effects of antiserum. Sn35 
incubated with a 1:100 dilution of antiserum was still able to induce cell damage and/or 
death to the host cells (Figure 25). Incubation with pre-immunized serum also had no 
effect on cytotoxicity (data not shown). Assays were repeated with antiserum dilutions of 
1:1000 and similar results were observed. 
 Furthermore, confocal assays were performed on the VK2 cell line to determine if 
antiserum blocked the adherence and/or invasion of host cells. Sn35 incubated with a 
1:100 dilution of antiserum was still able to invade the VK2 cells, as shown in Figure 26. 
Again, incubation with pre-immunized serum had no effect on invasion (data not 
shown). Assays were repeated with antiserum dilutions of 1:1000, and similar results 
were observed. 
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Figure 25. Inhibition of Sn35 cytotoxicity to JEG-3 cells. Bacteria were grown in 
SBHI + HS anaerobically overnight. Bacteria were standardized to an OD600nm = 0.1, 
and incubated with a 1:100 dilution of antiserum for 30 minutes at 37C. Bacteria were 
added to JEG-3 cells for 4 hours. Cells were washed after incubation, and trypan blue 
was added for 4 minutes to determine cell viability. Light microscopy images were taken 
after the trypan blue incubation. This experiment was repeated with a 1:1000 dilution of 
antiserum, with similar results. 
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Figure 26. Inhibition of Sn35 adherence to VK2 cells. Bacteria were grown in SBHI + 
HS anaerobically overnight. Bacteria (green) were standardized to an OD600nm = 0.150, 
and incubated with a 1:100 dilution of antiserum for 30 minutes at 37C. Bacteria were 
added to VK2 cells (red) for 15 minutes. Cells were washed after bacterial incubation to 
remove any nonadherent bacteria. Adherence was observed by confocal microscopy. 
This experiment was repeated with a 1:1000 dilution of antiserum, with similar results. 
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Discussion 
 
 
 Although Sneathia has been implicated in a number of obstetric complications 
and is one of the most common bacterial species isolated from amniotic fluid, the 
specific role of S. amnii strain Sn35 in preterm births caused by MIAC is still unclear. 
Through this study, the pathogenic potential of Sn35 was further characterized by 
assessing its effects on host cells, as well as its production of a putative virulence 
determinant.  
 The first research focus of this study was on the pathogenicity of Sn35 and its 
effect on various cell lines. It was hypothesized that Sn35 damaged and/or traversed 
host cell barriers formed during pregnancy, allowing it to invade the amniotic cavity. This 
hypothesis was confirmed, as our data demonstrates the ability of Sn35 to adhere, 
invade, and kill host cells.  
 In the current study, MIAC is modeled using immortalized and primary cell lines. 
While these models are able to provide some insight on bacterial-host cell interactions, 
they leave much to be desired. At this time, the specific cell target of Sn35 is unknown. 
Because fetal membranes are multi-layered and contain a variety of cell types, it’s 
possible that the host cells upon which Sn35 acts were not tested in this study. Primary 
HAECs were thought to be the best model for this focus; however, isolation and 
maintenance of these cells was difficult.  
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 Another obstacle to overcome is the translation of studies in vitro to infection in 
vivo. The placenta is designed to withstand a growing fetus for 9 months; even in cases 
of very preterm birth, such as the circumstance under which Sn35 was isolated, 
membranes have been in place for several weeks. Currently, it is not known how long it 
takes for Sn35 to access the amniotic cavity in vivo. We assume that this process is 
gradual, and most likely doesn’t occur in the short time periods that we have tested in 
vitro. Relevant studies have utilized mice, rabbit, and sheep models to study preterm 
birth and therapeutic targets aimed at improving neonatal outcome66. The ideal animal 
model for human pregnancy is the nonhuman primate, as their placentation and 
hormonal events occurring during pregnancy most closely resemble those of humans66. 
While animal models were not used for this study, further characterization of Sn35 in the 
context of preterm birth would benefit from their use.  
 The second objective concentrated on the identification of putative virulence 
determinants that could cause the observed pathogenic effects seen with Sn35-treated 
host cells. It was hypothesized that some virulence factor must be produced in order for 
cytopathogenicity to occur. Bioinformatic analyses identified a protein within Sn35 that 
had homology to haemagluttinin domains/repeats and adhesins. A putative Type Vb 
two-partner secretion system was identified as being the possible mechanism by which 
the putative virulence factor is secreted; a putative transporter gene was identified 
directly upstream of the putative virulence gene, indicating that the two genes are 
components of a two-partner secretion system. 
 The third objective focused on characterizing the function of the putative 
virulence factor. It was hypothesized that the putative virulence factor was acting as a 
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cytotoxin or adhesin. At this time, this hypothesis has yet to be confirmed, as antiserum-
treated bacteria were still able to invade host cells and induce cell damage and/or 
death. This could be due to a number of reasons; one plausible explanation is that TvbA 
is acting as neither a cytotoxin nor an adhesin. According to bioinformatic analyses, this 
is not likely, as the majority of known protein sequences that produce significant 
alignment with TvbA are adhesins or toxins.  
 A second explanation is that the polyclonal antiserum is not specific for many of 
the epitopes of native TvbA. The AS01 fragment used for polyclonal antiserum 
production may have a different conformation compared to native TvbA; this would 
result in the generation of antibodies specific to epitopes found on the fragment, but not 
the native protein. One additional explanation is that the antibodies specific for native 
TvbA epitopes could be blocked from binding due to steric hindrance. It’s possible that 
the antibodies within the antiserum are too bulky to bind to their specific epitopes. 
Additional experiments with the polyclonal antiserum, to include antibody fragmentation, 
will need to be performed to confirm or disprove this hypothesis. 
 Surprisingly, native TvbA was detected at ~250 kDa or above in all Western 
analyses. Currently, the genome sequence of Sn35 places the protein size at ~180 kDa. 
It’s possible that several repeats exist within the TvbA sequence, and misassemblies 
during genome sequencing caused the collapsing of these repeats. Post-translational 
modification, such as glycosylation or phosphorylation, would also explain the increase 
in protein size. An increase of ~60 kDa or higher, as observed in our analyses, could 
indicate modifications at multiple amino acids. Finally, TvbA could be forming a dimer. 
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This would explain the presence of smaller bands (~180 kDa) seen during temporal 
expression studies.   
 Collectively, the results of this study signify the need for further research into S. 
amnii strain Sn35 and the role it plays in preterm birth. Although Sn35 is not solely 
responsible for eliciting MIAC and PPROM, there is no doubt that it possesses the 
pathogenicity potential to contribute to these obstetric complications. The presence of 
Sn35 in vaginal and AF samples acquired from preterm births makes the organism one 
worth studying. While the findings presented in this work have further built upon the 
current understanding of Sn35, they have only scratched the surface. Therefore, having 
a better understanding of this organism will, in turn, result in a more complete 
knowledge of how MIAC, PPROM, and, ultimately, preterm birth develop.  
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